Literature DB >> 25331706

The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicans.

Nathan P Wiederhold1, Laura K Najvar2, Annette W Fothergill3, Dora I McCarthy3, Rosie Bocanegra2, Marcos Olivo2, William R Kirkpatrick2, Michael P Everson4, Frederick P Duncanson4, Thomas F Patterson2.   

Abstract

The in vitro and in vivo activity of the inositol acyltransferase inhibitor E1210 was evaluated against echinocandin-resistant Candida albicans. E1210 demonstrated potent in vitro activity, and in mice with invasive candidiasis caused by echinocandin-resistant C. albicans, oral doses of 10 and 40 mg E1210/kg of body weight twice daily significantly improved survival and reduced fungal burden compared to those of controls and mice treated with caspofungin (10 mg/kg/day). These results demonstrate the potential use of E1210 against resistant C. albicans infections.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25331706      PMCID： PMC4291422          DOI： 10.1128/AAC.03944-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis.

Authors:  Nao-Aki Watanabe; Mamiko Miyazaki; Takaaki Horii; Koji Sagane; Kappei Tsukahara; Katsura Hata
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

Review 2.  Candida albicans cell wall proteins.

Authors:  W LaJean Chaffin
Journal:  Microbiol Mol Biol Rev       Date:  2008-09       Impact factor: 11.056

3.  Comparison of anidulafungin's and fluconazole's in vivo activity in neutropenic and non-neutropenic models of invasive candidiasis.

Authors:  N P Wiederhold; L K Najvar; R Bocanegra; W R Kirkpatrick; T F Patterson
Journal:  Clin Microbiol Infect       Date:  2011-11-30       Impact factor: 8.067

4.  Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods.

Authors:  Mariana Castanheira; Frederick P Duncanson; Daniel J Diekema; Josep Guarro; Ronald N Jones; Michael A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

5.  Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methods.

Authors:  Michael A Pfaller; Naoaki Watanabe; Mariana Castanheira; Shawn A Messer; Ronald N Jones
Journal:  J Antimicrob Chemother       Date:  2011-08-25       Impact factor: 5.790

6.  In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method.

Authors:  Michael A Pfaller; Katsura Hata; Ronald N Jones; Shawn A Messer; Gary J Moet; Mariana Castanheira
Journal:  Diagn Microbiol Infect Dis       Date:  2011-06-22       Impact factor: 2.803

7.  In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods.

Authors:  Michael A Pfaller; Frederick Duncanson; Shawn A Messer; Gary J Moet; Ronald N Jones; Mariana Castanheira
Journal:  Antimicrob Agents Chemother       Date:  2011-08-15       Impact factor: 5.191

8.  Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans.

Authors:  Nathan P Wiederhold; Laura K Najvar; Rosie A Bocanegra; William R Kirkpatrick; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

9.  Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis.

Authors:  Katsura Hata; Takaaki Horii; Mamiko Miyazaki; Nao-Aki Watanabe; Miyuki Okubo; Jiro Sonoda; Kazutaka Nakamoto; Keigo Tanaka; Syuji Shirotori; Norio Murai; Satoshi Inoue; Masayuki Matsukura; Shinya Abe; Kentaro Yoshimatsu; Makoto Asada
Journal:  Antimicrob Agents Chemother       Date:  2011-07-25       Impact factor: 5.191

10.  Gene overexpression/suppression analysis of candidate virulence factors of Candida albicans.

Authors:  Yue Fu; Guanpingsheng Luo; Brad J Spellberg; John E Edwards; Ashraf S Ibrahim
Journal:  Eukaryot Cell       Date:  2008-01-04
View more
  20 in total

Review 1.  The antifungal pipeline: a reality check.

Authors:  John R Perfect
Journal:  Nat Rev Drug Discov       Date:  2017-05-12       Impact factor: 84.694

2.  In Vitro Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017.

Authors:  M A Pfaller; M D Huband; R K Flamm; P A Bien; M Castanheira
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

3.  Manogepix (APX001A) Displays Potent In Vitro Activity against Human Pathogenic Yeast, but with an Unexpected Correlation to Fluconazole MICs.

Authors:  Maiken Cavling Arendrup; Karin Meinike Jørgensen
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

Review 4.  Targeting the GPI biosynthetic pathway.

Authors:  Usha Yadav; Mohd Ashraf Khan
Journal:  Pathog Glob Health       Date:  2018-02-27       Impact factor: 2.894

Review 5.  Biosynthesis of GPI-anchored proteins: special emphasis on GPI lipid remodeling.

Authors:  Taroh Kinoshita; Morihisa Fujita
Journal:  J Lipid Res       Date:  2015-11-12       Impact factor: 5.922

6.  APX001A In Vitro Activity against Contemporary Blood Isolates and Candida auris Determined by the EUCAST Reference Method.

Authors:  Maiken Cavling Arendrup; Anuradha Chowdhary; Karen M T Astvad; Karin Meinike Jørgensen
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

7.  Therapeutic Potential of Fosmanogepix (APX001) for Intra-abdominal Candidiasis: from Lesion Penetration to Efficacy in a Mouse Model.

Authors:  Annie Lee; Ning Wang; Claire L Carter; Matthew Zimmerman; Véronique Dartois; Karen Joy Shaw; David S Perlin; Yanan Zhao
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

8.  In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris.

Authors:  Christopher L Hager; Emily L Larkin; Lisa Long; Fatima Zohra Abidi; Karen J Shaw; Mahmoud A Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

Review 9.  Antifungal resistance: current trends and future strategies to combat.

Authors:  Nathan P Wiederhold
Journal:  Infect Drug Resist       Date:  2017-08-29       Impact factor: 4.003

Review 10.  New Horizons in Antifungal Therapy.

Authors:  Kaila M Pianalto; J Andrew Alspaugh
Journal:  J Fungi (Basel)       Date:  2016-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.